Xenetic Biosciences prices $4.5M underwritten offering of 735,000 shares at $6.12/share

Xenetic Biosciences, Inc.

Offering of 735,000 common shares at $6.12 each for gross proceeds of ~$4.5M; net proceeds ~$3.9M after discounts and expenses.
Expected to close on or about October 14, 2025, subject to customary closing conditions.
Net proceeds to be used for working capital, general corporate purposes, and advancement of DNase technology.
Canaccord Genuity is sole bookrunner; offering made under effective shelf registration statement (File No. 333-282756).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.